1. Background
2. Objectives
3. Patients and Methods
3.1. Isolation and Culturing
3.2. Antimicrobial Susceptibility Test
3.3. DNA Purification and Polymerase Chain Reaction for Detection of Class 1 and 2 Integrons
3.4. Gradient Polymerase Chain Reaction and Detection of Genomic Islands Integrase Gene
3.5. DNA Sequencing
4. Results
4.1. Disk Diffusion
4.2. Detection of Class 1 and 2 Integrons and Genomic Islands Integrase Gene
4.3. Nucleotide Sequencing of Integrase Gene Attributed to Genomic Islands
| Antibiotics b | Resistance | Sensitive | Intermediate |
|---|---|---|---|
| A | 19 (95) | 1 (5) | 0 (0) |
| CIP | 9 (45) | 11 (55) | 0 (0) |
| CD | 20 (100) | 0 (0) | 0 (0) |
| C | 20 (100) | 0 (0) | 0 (0) |
| TE | 20 (100) | 0 (0) | 0 (0) |
| CRO | 10 (50) | 10 (50) | 0 (0) |
| ATH | 2 (10) | 18 (90) | 0 (0) |
| TM | 0 (0) | 19 (95) | 1 (5) |
| SXT | 0 (0) | 20 (100) | 0 (0) |
a Data are presented as No. (%).
bA, Amoxicillin: 10 µg; CIP, Ciprofloxacin: 5 µg; CRO, Ceftriaxone: 30 µg; CD, Clindamycin: 2 µg; ATH, Azithromycin: 15 µg; C, Chloramphenicol: 30 µg; TE, Tetracycline: 30 µg; TM, Trimethoprim: 5 µg; SXT, Sulfamethoxazole: 30 µg.
| Antibiotics b | TE,C,A | TE,C,A,CIP | TE,C,A,CRO | TE,C,A,CIP,CRO | TE,C,A,CIP,CRO,ATH |
|---|---|---|---|---|---|
| Resistant | 95% | 45% | 50% | 40% | 5% |
a Data are presented as No. (%).
bA, Amoxicillin: 10 µg; CIP, Ciprofloxacin: 5 µg; CRO, Ceftriaxone: 30 µg; CD, Clindamycin: 2 µg; ATH, Azithromycin: 15 µg; C, Chloramphenicol: 30 µg; TE, Tetracycline: 30 µg; TM, Trimethoprim: 5 µg; SXT, Sulfamethoxazole: 30 µg.
